US patent for Reliant Technologies IR CO(2) laser technology:
This article was originally published in Clinica
Executive Summary
Reliant Technologies has been awarded US Patent No 5,429,882 for its Infrared CO(2) Laser Technology with a Blue- Green Aiming Beam. Reliant, of Foster City, California, plans to license the technology to selected US and foreign strategic OEM partners.
You may also be interested in...
Civica Rx Gets $55m Investment
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.
Pfizer’s US Rituximab Launched At A 24% Discount
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
Teva Leapfrogs Mylan And Sandoz On Linaclotide
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: